logo

For the Inventor, By the Inventor

Summit, NJ, United States of America

Abraxis Bioscience, LLC


USPTO Granted Patents = 80



Trademarks = 13

Forward Citations = 2,587

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Neil P Desai (71 out of 142 patents)

silverMedal Patrick Soon-Shiong (45 out of 447 patents)

bronzeMedal Vuong Trieu (27 out of 35 patents)

4.  Willard Foss (8 out of 8 patents)

5.  Chunlin Tao (8 out of 32 patents)

6.  Viktor Peykov (7 out of 7 patents)

7.  Daniel W Pierce (5 out of 11 patents)

8.  Andrew Yang (5 out of 15 patents)

9.  Tapas De (5 out of 5 patents)

10.  Markus Renschler (4 out of 4 patents)

11.  Rajesh R Shinde (3 out of 14 patents)

12.  Kirk Patrick Seward (3 out of 43 patents)

13.  Zachary Yim (3 out of 3 patents)

14.  Cheng Zhi Yu (3 out of 3 patents)

15.  Qinwei Wang (2 out of 14 patents)


Core Competencies:
Nanoparticle Compositions
mTOR Inhibitors
Albumin Therapeutics
Cancer Treatment
Polymeric Excipients
SPARC Binding ScFvs
Drug Delivery Enhancement
Epithelioid Cell Tumors
Breast Cancer Therapy
Hepatocellular Carcinoma
Lung Cancer Treatment
Pancreatic Cancer

80 patents:

1. 12324860 - Methods of treating central nervous system disorders via administration of nanoparticles of an mTOR inhibitor and an albumin (2025-06-10),
2. 12133844 - Methods of treating epithelioid cell tumors (2024-11-05),
3. 12061183 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug (2024-08-13),
4. 11944708 - Methods of treating central nervous system disorders via administration of nanoparticles of an mTOR inhibitor and an albumin (2024-04-02),
5. 11497737 - Pharmaceutical compositions of albumin and rapamycin (2022-11-15),
6. 11320416 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug (2022-05-03),
7. 10973806 - Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin (2021-04-13),
8. 10900951 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel (2021-01-26),
9. 10744110 - Methods of treating lung cancer (2020-08-18),
10. 10705070 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug (2020-07-07),
11. 10682420 - Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane (2020-06-16),
12. 10660965 - Methods of enhancing drug delivery and effectiveness of therapeutic agents (2020-05-26),
13. 10555912 - Use of polymeric excipients for lyophilization or freezing of particles (2020-02-11),
14. 10527604 - Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel (2020-01-07),
15. 10413531 - Methods of treating bladder cancer (2019-09-17),
Abraxis BioScience, LLC is a leading science-based biopharmaceutical company focused on developing and commercializing innovative therapies for patients with challenging medical conditions. With a strong commitment to research and development, Abraxis specializes in the development of targeted therapeutics and delivery systems, including the proprietary nab® technology platform. The company's mission is to improve patients' lives by providing them with high-quality, effective, and safe treatments.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
80 Patents

#3 in Summit, NJ

#205 in New Jersey

#4,442 in US

#9,071 in the World

...
Summit, NJ, United States of America

Abraxis Bioscience, LLC

Forward Citations = 2,587

29 inventors:

goldMedal Neil P Desai (71 out of 142 patents)

silverMedal Patrick Soon-Shiong (45 out of 447 patents)

bronzeMedal Vuong Trieu (27 out of 35 patents)

4.  Willard Foss (8 out of 8 patents)

5.  Chunlin Tao (8 out of 32 patents)

Please report any incorrect information to support@idiyas.com
Loading…